Home About Us Pipeline News Investors Contacts Careers


News

Recent Press Releases Archives

Recent Press Releases

2015 News Releases

Dec. 30, 2015 - Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 29, 2015 - Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 23, 2015 - ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card
Read

Dec. 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read

Dec. 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea
Read

Dec. 11, 2015 - Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) at the 2015 San Antonio Breast Cancer Symposium
Read

Dec. 10, 2015 - Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium
Read

Dec. 10, 2015 - Puma Biotechnology Announces Results of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer
Read

Nov. 30, 2015 - Puma Biotechnology Provides Update from Meeting with European Medicines Agency
Read

Nov. 13, 2015 - Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS)
Read

Nov. 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results
Read

Nov. 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference
Read

Sept. 26, 2015 - Puma Biotechnology Announces Presentation of Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients
Read

Sept. 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation
Read

Aug. 10, 2015 - Puma Biotechnology Reports Second Quarter 2015 Financial Results
Read

June 4, 2015 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference
Read

June 1, 2015 - Puma Biotechnology Announces Phase III Trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET Trial) Demonstrates Statistically Significant Improvement in Disease Free Survival
Read

May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference
Read

May 13, 2015 - Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting
Read

May 12, 2015 - Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference
Read

May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results
Read

May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference
Read

April 30, 2015 - Puma Biotechnology to Present at Deutsche Bank Health Care Conference
Read

April 14, 2015 - Puma Biotechnology Expands Cohort in Phase II Trial of PB272 in HER2 Mutation Positive Cancer Patients
Read

Mar. 10, 2015 - Puma Biotechnology Initiates Phase II Trial of PB272 in Early Stage HER2-Positive Breast Cancer
Read

Mar. 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results
Read

Feb. 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference
Read

Feb. 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Conference
Read

Feb. 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference
Read

Jan. 27, 2015 - Puma Biotechnology Closes $218 Million Public Offering of Common Stock
Read

Jan. 22, 2015 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares
Read

Jan. 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock
Read

Jan. 20, 2015 - Puma Biotechnology Announces Proposed Public Offering
Read

Jan. 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference
Read




Corporate Fact Sheet

Puma Biotechnology, Inc.

10880 Wilshire Blvd., Suite 2150
Los Angeles, CA 90024
424-248-6500 Main
424-248-6501 Fax